Yangy, Yuncong team published research in Acta Pharmaceutica Sinica B in 2020 | 2905-24-0

Safety of 3-Bromobenzenesulfonyl chloride, 3-Bromobenzenesulfonyl chloride is an aryl sulfonyl chloride derivative. It participates in the synthesis of N-sulfonylanthranilic acid derivatives and potent P1′ benzenesulfonyl azacyclic urea human immunodeficiency virus (HIV) protease inhibitors.
3-Bromobenzenesulfonyl chloride is a molecule that can be used to inhibit the uptake of 3-bromobenzoate. The inhibition of uptake is due to the desymmetrization of the unsymmetrical, 3-bromobenzoate. This reaction leads to an increase in the concentration of 3-bromobenzoate. Inhibition studies have shown that 3-bromobenzenesulfonyl chloride has an inhibitory effect on cancer cells and apoptosis pathway. The structural studies have shown that this drug is synthetic and biphenyl can be synthesized from it. T-cell lymphomas have been shown to be inhibited by this drug and heart disease has also been inhibited., 2905-24-0.

The class of organic compounds having covalently a bonded chlorine atom is called organic chlorides. 2905-24-0, formula is C6H4BrClO2S, Name is 3-Bromobenzenesulfonyl chloride. Their wide structural variety and divergent chemical properties lead to a broad range of named reactions and applications. Safety of 3-Bromobenzenesulfonyl chloride.

Yangy, Yuncong;Zhangy, Sirui;Qian, Zhouy;Zhang, Chen;Gao, Yuqi;Wang, Hao;Li, Zhe;Wu, Deyan;Wu, Yinuo;Huang, Yi-You;Guo, Lei;Luo, Hai-Bin research published 《 Discovery of highly selective and orally available benzimidazole-based phosphodiesterase 10 inhibitors with improved solubility and pharmacokinetic properties for treatment of pulmonary arterial hypertension》, the research content is summarized as follows. Optimization efforts were devoted to discover novel PDE10A inhibitors in order to improve solubility and pharmacokinetics properties for a long-term therapy against pulmonary arterial hypertension (PAH) starting from the previously synthesized inhibitor A. As a result, a potent and highly selective PDE10A inhibitor, 14·3HCl (half maximal inhibitory concentration, IC50 Z 2.8 nmol/L and >3500-fold selectivity) exhibiting desirable solubility and metabolic stability with a remarkable bioavailability of 50% was identified with the aid of efficient methods of binding free energy predictions. Animal PAH studies showed that the improvement offered by 14·3HCl [2.5 mg/kg, oral administration (p.o.)] was comparable to tadalafil (5.0 mg/kg, p.o.), verifying the feasibility of PDE10A inhibitors for the anti- PAH treatment. The crystal structure of the PDE10A-14 complex illustrates their binding pattern, which provided a guideline for rational design of highly selective PDE10A inhibitors.

Safety of 3-Bromobenzenesulfonyl chloride, 3-Bromobenzenesulfonyl chloride is an aryl sulfonyl chloride derivative. It participates in the synthesis of N-sulfonylanthranilic acid derivatives and potent P1′ benzenesulfonyl azacyclic urea human immunodeficiency virus (HIV) protease inhibitors.
3-Bromobenzenesulfonyl chloride is a molecule that can be used to inhibit the uptake of 3-bromobenzoate. The inhibition of uptake is due to the desymmetrization of the unsymmetrical, 3-bromobenzoate. This reaction leads to an increase in the concentration of 3-bromobenzoate. Inhibition studies have shown that 3-bromobenzenesulfonyl chloride has an inhibitory effect on cancer cells and apoptosis pathway. The structural studies have shown that this drug is synthetic and biphenyl can be synthesized from it. T-cell lymphomas have been shown to be inhibited by this drug and heart disease has also been inhibited., 2905-24-0.

Referemce:
Chloride – Wikipedia,
Chlorides – an overview | ScienceDirect Topics